Synapsin-Promoted Caveolin-1 Gene Therapy as a Rectifier of Convergent Autophagic Collapse: A Critical Evaluation for the Oskar Fischer Prize

1. Introduction

1.1 The Etiological Impasse in Alzheimer's Disease Research

The field of Alzheimer's Disease (AD) research stands at a critical juncture. For over three decades, the scientific community has been largely unified under the banner of the amyloid cascade hypothesis, which posits that the aggregation of amyloid-beta (Aβ) peptides into extracellular plaques is the primary, initiating event in AD pathogenesis.[1] This hypothesis suggests that Aβ deposition triggers a downstream sequence of neurofibrillary tangle formation, synaptic loss, and eventual neuronal death. However, this linear causality has been severely challenged by the persistent failure of amyloid-centric therapeutics in late-stage clinical trials. Agents such as solanezumab and bapineuzumab, despite effectively engaging their amyloid targets, have failed to arrest cognitive decline or restore synaptic function.[1]

This disconnect between plaque clearance and functional recovery suggests that Aβ accumulation may be a symptom of a deeper, more fundamental cellular failure rather than the singular architect of the disease. It necessitates a paradigm shift toward identifying "proximal" mechanisms of neurodegeneration—cellular lesions that compromise the neuron's resilience to stress long before, or perhaps in parallel with, the aggregation of proteins. The Oskar Fischer Prize serves as a catalyst for this intellectual expansion, seeking comprehensive explanatory models that can integrate the diverse pathologies of AD into a coherent etiological framework.

1.2 The Convergent Autophagic Collapse (CAC) Framework

In response to the stagnation of the amyloid paradigm, the Convergent Autophagic Collapse (CAC) framework has emerged as a robust theoretical model. The CAC hypothesis posits that the fundamental lesion in AD is not protein aggregation per se, but the progressive failure of the neuron's waste management and recycling infrastructure: the autophagy-lysosome pathway (ALP). Neurons, as post-mitotic cells with extreme metabolic demands and complex morphologies, are uniquely vulnerable to the accumulation of damaged organelles and protein aggregates.

The CAC framework proposes a specific, lipid-centric sequence of pathogenesis:

1. **Membrane Lipid Dysregulation:** The cycle initiates with the toxic accumulation of lipids, specifically cholesterol and sphingolipids, within the endolysosomal system.
2. **V-ATPase Inhibition:** Excess membrane cholesterol rigidifies the lysosomal membrane or allosterically inhibits the Vacuolar-type H+-ATPase (V-ATPase) pump, the primary enzyme responsible for lysosomal acidification.[2]
3. **Lysosomal Alkalinization:** The inhibition of V-ATPase leads to a rise in intralumenal pH. Since lysosomal hydrolases (e.g., cathepsins) require an acidic environment (pH 4.5–5.0) for activation, alkalinization renders the lysosome metabolically inert.[4]
4. **Autophagic Blockade:** The failure of lysosomal degradation creates a "traffic jam." Autophagosomes cannot fuse effectively with lysosomes or, if they do, their cargo is not digested. This results in the accumulation of autophagic vacuoles (AVs) packed with undigested mitochondria (mitophagy failure) and protein aggregates.[6]
5. **Synaptic Failure:** The blockade disrupts the recycling of synaptic vesicles and neurotransmitter receptors (e.g., AMPARs, NMDARs), leading to synaptic collapse and cognitive failure, independent of the extracellular plaque burden.[7]

Under the tenets of CAC, a truly disease-modifying therapy must do more than clear extracellular debris; it must rectify the internal "digestive" failure of the neuron, likely by restoring membrane lipid homeostasis and re-acidifying the lysosome.

1.3 The Candidate Investigation: SynCav1 Gene Therapy

This thesis presents a comprehensive evaluation of the study titled *"Synapsin-promoted caveolin-1 gene therapy preserves hippocampal function in a mouse model of Alzheimer's Disease"* by Head et al..[1] The investigators explore the therapeutic potential of **Caveolin-1 (Cav-1)**, a scaffolding protein integral to the formation of membrane lipid rafts (MLRs) and caveolae. Observing that Cav-1 expression is significantly diminished in the hippocampus of aging AD mice and human patients, the authors utilized an adeno-associated virus serotype 9 (AAV9) vector to re-express Cav-1 specifically in neurons.

The study reports that this intervention, **AAV9-SynCav1**, preserved hippocampal learning, memory, and synaptic ultrastructure in the APPSwePS1d9 mouse model of AD. Most significantly, and consistent with the predictions of the CAC framework, these neuroprotective effects occurred **independently of Aβ plaque reduction**.[1] This thesis will dissect the molecular and proteomic data presented by Head et al. to argue that SynCav1 acts as a rectifier of the Convergent Autophagic Collapse, primarily by restoring non-vesicular cholesterol transport and stabilizing synaptic receptor recycling.

---

2. Theoretical Background: The Biology of Membrane Scaffolds and Lysosomal Flux

To properly evaluate the efficacy of SynCav1 within the CAC framework, one must first establish the critical role of Caveolin-1 in membrane biology and its intersection with autophagic flux.

2.1 Caveolin-1 as a Master Regulator of Membrane Architecture

Caveolin-1 is the principal structural component of caveolae, flask-shaped invaginations of the plasma membrane enriched in cholesterol and sphingolipids.[8] Beyond its structural role, Cav-1 functions as a master scaffolding protein within Membrane Lipid Rafts (MLRs), organizing diverse signaling complexes including neurotrophin receptors (TrkB), neurotransmitter receptors, and ion channels.[10]

The "Scaffolding Hypothesis" suggests that Cav-1 concentrates these receptors and their downstream effectors (e.g., Src kinases) into discrete microdomains, ensuring efficient signal transduction. Loss of Cav-1, as observed in AD and aging, leads to the disassembly of these rafts, causing receptors to disperse, internalize, and degrade.[11]

2.2 The Caveolin-Autophagy-Lysosome Axis

Recent literature has expanded the role of Cav-1 beyond the plasma membrane, implicating it directly in the regulation of autophagy and lysosomal function. The relationship is complex and context-dependent:

- **Regulation of Autophagic Flux:** Cav-1 deficiency has been shown to promote autophagy activation in some contexts (e.g., endothelial cells under stress) by releasing ATG5-ATG12 complexes.[12] However, chronic loss of Cav-1 in the context of neurodegeneration appears to disrupt the structural integrity of lysosomes and impair the fusion of autophagosomes with lysosomes.[13]
- **Lysosomal Stability:** Cav-1 regulates lysosomal pH and membrane stability. Loss of Cav-1 has been linked to lysosomal alkalinization and decreased activity of lysosomal enzymes.[4] Furthermore, Cav-1 protects against lysosomal membrane permeabilization (LMP), a catastrophic event that leaks hydrolases into the cytoplasm, triggering cell death.[15]
- **V-ATPase Interaction:** Crucially, Cav-1 physically interacts with the V-ATPase complex. Studies suggest that Cav-1 acts as a chaperone or stabilizer for V-ATPase assembly, particularly the V1 and V0 domains. Disruption of lipid rafts (where V-ATPase localizes) or loss of Cav-1 can lead to V-ATPase disassembly and failure of acidification.[13]

The Mechanism of Convergent Autophagic Collapse



A schematic representation of the Convergent Autophagic Collapse (CAC) framework. The cycle initiates with membrane lipid dysregulation, specifically cholesterol accumulation, which inhibits the V-ATPase proton pump. This leads to lysosomal alkalinization, preventing the degradation of autophagic cargo and resulting in a toxic accumulation of cellular waste and synaptic failure.

2.3 The Cholesterol-V-ATPase Inhibitory Loop

The CAC framework emphasizes that cholesterol accumulation is the primary driver of V-ATPase failure. Excess cholesterol in the lysosomal membrane increases membrane rigidity, preventing the conformational changes necessary for the V-ATPase rotary motor to pump protons.[2] Consequently, mechanisms that clear cholesterol from the lysosome—such as the NPC1 pathway or non-vesicular transport via contact sites—are essential for maintaining low lysosomal pH and high autophagic flux. If these pathways fail (e.g., due to loss of transport proteins), CAC ensues.

---

3. Methodology Critique: Experimental Design and Rigor

The validity of the findings by Head et al. rests on the rigor of their experimental design. The study utilized the **APPSwePS1d9** double transgenic mouse model, a robust system that

overexpresses chimeric mouse/human amyloid precursor protein (Mo/HuAPP695swe) and mutant human presenilin 1 (PS1-dE9).[1] This model rapidly develops amyloid pathology and cognitive deficits, making it a stringent testbed for therapeutic intervention.

3.1 Vector Design and Delivery Strategy

The therapeutic agent, **AAV9-SynCav1**, employs the Adeno-Associated Virus serotype 9 (AAV9), known for its high transduction efficiency in the central nervous system (CNS).[19]

- **Promoter Specificity:** The use of the human **synapsin (hSyn)** promoter restricts transgene expression to neurons.[1] This is a critical design choice to avoid off-target effects in glial cells or peripheral tissues (like the liver or heart), where Cav-1 overexpression could have deleterious effects, such as fibrosis or oncogenesis.[1]
- **Timing:** The vector was delivered via bilateral hippocampal stereotactic injection at 3 months of age (pre-symptomatic). Assessments were conducted at 9 and 11 months (symptomatic).[1] This "prevention" design tests the capacity of SynCav1 to confer resilience against developing pathology rather than reversing end-stage neurodegeneration.

3.2 Sample Size and Statistical Power

A common critique of preclinical neurodegeneration studies is insufficient statistical power. The Head et al. study addresses this by employing robust sample sizes for behavioral assays. The 9-month cohort included 15-19 mice per group, and the 11-month cohort included 17-22 mice per group.[1] These numbers exceed the standard n=10 often seen in the field, providing high confidence in the behavioral data. Statistical significance was determined using one-way ANOVA followed by Fisher's LSD or Tukey's multiple comparisons tests, with significance set at $p < 0.05$.[1]

3.3 Biochemical and Proteomic Approaches

The study utilized biochemical fractionation to isolate Membrane Lipid Rafts (MLRs) based on their buoyancy in sucrose gradients. This allowed the researchers to specifically analyze the "functional" pool of synaptic proteins rather than total cellular levels.[1] Furthermore, the inclusion of unbiased proteomics (LC-MS/MS) on these fractions provided a high-resolution view of the molecular landscape remodeling induced by SynCav1.[1]

---

4. Results Analysis: Structural and Functional Rescue

The findings presented by Head et al. demonstrate a comprehensive rescue of the AD phenotype at the behavioral, structural, and cellular levels.

4.1 Cognitive Preservation Independent of Amyloid

The most clinically relevant finding is the preservation of hippocampal-dependent memory. In the Fear Conditioning assay, which tests the ability of mice to learn and remember an association between an environment and an aversive stimulus, 9-month-old AD-SynRFP mice showed significant deficits. While wild-type (WT) mice exhibited freezing rates of approximately 50% during contextual recall, AD-SynRFP mice dropped to roughly 20-25%. Strikingly, **AD-SynCav1 mice recovered to approximately 40-45% freezing**, a performance statistically indistinguishable from the WT controls.[1]

This rescue effect was durable, persisting in the 11-month cohort. Crucially, immunofluorescence analysis (Figure S8) confirmed that **amyloid plaque load was identical** in AD-SynRFP and AD-SynCav1 mice.[1]

Table 1: Comparative Analysis of Cognitive Function and Pathology

Parameter	WT-SynRFP	AD-SynRFP	AD-SynCav1
Contextual Memory (9 mo)	Normal (~50% Freezing)	Impaired (~25% Freezing)	**Preserved** (~45% Freezing)
Contextual Memory (11 mo)	Normal	Impaired	**Preserved**
Amyloid Plaque Load	None	High	**High** (No Reduction)
Astrogliosis (GFAP)	Low	High	**High** (No Reduction)

Data derived from Figures 1 and S8 of Head et al..[1]

This result directly challenges the amyloid cascade hypothesis. If Aβ were the proximate cause of synaptic failure, the maintenance of high plaque load should preclude cognitive recovery. Instead, the data supports the CAC framework: SynCav1 renders the neuron **resilient** to the toxic presence of amyloid, likely by fortifying the internal cellular machinery against collapse.

4.2 Preservation of Synaptic Ultrastructure

Electron microscopy (EM) provided the structural correlate to the behavioral rescue. AD-SynRFP mice exhibited a significant reduction in the density of type I excitatory

asymmetric synapses and a decrease in the number of presynaptic vesicles (PSVs) per bouton.[1] Furthermore, their dendritic spines showed pathological morphology: "stubby" spines with increased neck diameter and reduced length, a shape associated with synaptic immaturity and failure.[1]

In contrast, SynCav1 treatment preserved synaptic density, vesicle numbers, and spine morphology (maintaining the mature "mushroom" shape) at levels comparable to WT mice.[1] This indicates that SynCav1 does not merely improve signaling efficiency but physically maintains the synaptic architecture against the erosive effects of the disease.

4.3 Restoration of MLR-Localized Signaling Complexes

The biochemical analysis revealed that in AD mice, essential signaling proteins—specifically **full-length TrkB (fl-TrkB)**, **Cav-1**, and **LRP1**—were displaced from the buoyant MLR fractions (fractions 4 and 5).[1]

- **TrkB:** The receptor for Brain-Derived Neurotrophic Factor (BDNF). Its localization to lipid rafts is essential for pro-survival signaling. Displacement leads to truncation or degradation.
- **LRP1:** The Low-Density Lipoprotein Receptor-Related Protein 1. It is critical for cholesterol uptake and Aβ clearance.

SynCav1 gene therapy successfully "re-scaffolds" these proteins, restoring their presence in the MLR fractions to WT levels.[1] This restoration of LRP1 is particularly significant for the CAC framework. LRP1 is a massive receptor heavily reliant on efficient endosomal recycling. Its preservation in SynCav1 mice acts as a strong proxy indicator that endosomal-lysosomal traffic, which is blocked in CAC, has been restored.

---

5. Proteomic Revelation: The Molecular Mechanism of Rescue

While the preservation of TrkB and LRP1 explains the synaptic resilience, the unbiased proteomics analysis performed on the MLR fractions provides the crucial "missing link" to the mechanism of Autophagic Collapse rectification. The analysis compared the MLR proteomes of AD-SynRFP vs. AD-SynCav1 mice and identified 168 significantly altered proteins.[1] Two specific hits—**Shisa9** and **KIAA1468 (RELCH)**—stand out as pivotal.

Differential Protein Expression in Hippocampal Lipid Rafts



Reconstruction of relative protein expression levels in hippocampal membrane lipid rafts (MLRs). Data indicates that key proteins downregulated in AD mice (Cav-1, Shisa9, RELCH/KIAA1468) are significantly restored in the SynCav1 treatment group, often exceeding Wild-Type levels due to overexpression.

Data sources: Head et al. (2020)

5.1 KIAA1468 (RELCH): The Cholesterol Release Valve

The protein **KIAA1468**, also known as **RELCH** (Rab11-binding protein containing LisH, coiled-coil, and HEAT repeats), was found to be significantly downregulated in the MLRs of AD mice but significantly upregulated/restored in SynCav1-treated mice.[1]

The biological function of RELCH is critical to the CAC hypothesis. RELCH has been identified

as a Rab11 effector protein that tethers recycling endosomes (REs) to the Trans-Golgi Network (TGN) via interaction with OSBP (Oxysterol Binding Protein).[23] This tethering facilitates the **non-vesicular transport of cholesterol** out of the endocytic system and back to the Golgi/ER.

- **In the AD State (Low RELCH):** The downregulation of RELCH in AD mice implies a failure of this cholesterol efflux pathway. Cholesterol, endocytosed via LRP1, becomes trapped in the endosome/lysosome system. As predicted by CAC, this accumulation leads to the rigidification of lysosomal membranes and the inhibition of V-ATPase.[3] The result is lysosomal alkalinization and autophagic failure.
- **In the SynCav1 State (Restored RELCH):** The therapy's restoration of RELCH expression likely re-establishes the structural tethers between endosomes and the TGN. This acts as a "metabolic release valve," allowing trapped cholesterol to exit the lysosome.
- **Mechanism of Rescue:** By clearing the cholesterol blockage, SynCav1 alleviates the inhibition of V-ATPase. This permits the re-acidification of the lysosome, the reactivation of hydrolases, and the clearance of the autophagic traffic jam.

Mechanistically, the loss of Cav-1 and RELCH in the AD brain leads to a sequestration of cholesterol in the lysosome, inhibiting the V-ATPase. SynCav1 restoration acts as a molecular relief valve, re-establishing the RELCH-mediated tunnel to the TGN. This finding provides a direct molecular mechanism explaining *how* SynCav1 prevents autophagic collapse: it fixes the lipid dysregulation that drives lysosomal failure.

5.2 Shisa9: Stabilizing the Synapse

The second major proteomic hit was **Shisa9** (also known as CKAMP44), which was the most downregulated protein in AD MLRs ($log_2 = -5.9$) and the second most upregulated protein following SynCav1 treatment.[1]

Shisa9 is a transmembrane auxiliary subunit of AMPA receptors (AMPARs) found in the postsynaptic density (PSD).[24] It plays a crucial role in regulating the trafficking, gating, and stabilization of AMPARs at the synapse.

- **Role in Plasticity:** Shisa9 promotes the surface expression of AMPARs and is essential for short-term synaptic plasticity and the maintenance of Long-Term Potentiation (LTP) in the hippocampus.[24]
- **Connection to CAC:** Synaptic receptors are constitutively recycled via the endosomal pathway. In the state of Autophagic Collapse, this recycling is blocked; receptors are either trapped in stagnant endosomes or mis-sorted for degradation. The profound loss of Shisa9 in AD mice reflects this failure of synaptic maintenance.
- **SynCav1 Effect:** By restoring the MLR scaffold and lysosomal flux (via RELCH), SynCav1 ensures that Shisa9 can be properly trafficked to the synapse. Once there, Shisa9 stabilizes AMPARs, preserving the "mushroom" spine morphology and functional

plasticity (memory) observed in the behavioral assays.[29]

Shisa9, therefore, represents the downstream effector of the rescue. While RELCH fixes the "plumbing" (lysosomal flux), Shisa9 rebuilds the "structure" (synaptic connectivity).

---

6. Synthesis: SynCav1 as a Rectifier of CAC

Integrating the behavioral, structural, and proteomic data, we can construct a unified model of SynCav1 efficacy through the lens of Convergent Autophagic Collapse.

1. **The Lesion:** In AD, a loss of neuronal Cav-1 leads to the destabilization of MLRs. This causes the downregulation of **RELCH**, breaking the non-vesicular transport link between endosomes and the Golgi.
2. **The Collapse:** Cholesterol accumulates in the endolysosomal system due to the block in RELCH-mediated efflux. This cholesterol buildup inhibits V-ATPase, causing lysosomal pH to rise. The ALP collapses, leading to the accumulation of undigested cargo (CAC).
3. **The Synaptic Consequence:** Without functional recycling pathways, synaptic organizers like **Shisa9** and **LRP1** are depleted from the membrane. TrkB signaling fails. Synapses wither (stubby spines) and memory is lost.
4. **The SynCav1 Rescue:** AAV9-SynCav1 restores the MLR scaffold. This stabilizes **RELCH**, re-opening the cholesterol efflux pathway. Lysosomes clear cholesterol, re-acidify, and resume degradation.
5. **The Outcome:** With the "traffic jam" cleared, **Shisa9** and **TrkB** are correctly trafficked to the synapse. They stabilize AMPARs and sustain pro-survival signaling, preserving cognitive function despite the continued presence of extracellular amyloid plaques.

This model reframes SynCav1 not merely as a scaffolding agent, but as a **metabolic resilience therapy** that targets the specific lipid-lysosome interface defined by the CAC framework.

---

7. Comparative Analysis and Clinical Translation

7.1 Comparison with Other Gene Therapies

Previous gene therapy attempts in AD, such as the delivery of Nerve Growth Factor (NGF) via AAV2 [1], failed in Phase 2 clinical trials. The Head et al. paper suggests a reason for this failure: providing the ligand (NGF) is useless if the receptor (TrkA/TrkB) is not properly positioned on the membrane. By targeting the *scaffold* (Cav-1) rather than the ligand, SynCav1 ensures that endogenous neurotrophins can signal effectively. This makes SynCav1 a "force multiplier" for the brain's natural repair mechanisms.

7.2 Independent Validation and Clinical Status

The potential of SynCav1 has been recognized beyond the academic sphere. The technology has been licensed to **Eikonoklastes Therapeutics**, a biotech company that has received Orphan Drug Designation (ODD) from the FDA for the use of SynCav1 (codenamed **ET-101**) in Amyotrophic Lateral Sclerosis (ALS).[31] While the current focus is on AD, the underlying mechanism—restoring MLR scaffolding and lysosomal flux—is applicable to multiple neurodegenerative diseases characterized by protein aggregation and autophagic failure, including ALS and Parkinson's Disease.[33]

Independent studies have also begun to corroborate the role of the identified targets. For instance, recent large-scale transcriptomic analyses have confirmed the downregulation of **Shisa9** and **RELCH** in human AD brains [35], validating the relevance of the mouse model findings to human pathology. Furthermore, Cav-1 deficiency has been independently linked to impaired synaptic transmission and V-ATPase disassembly in other labs, reinforcing the mechanistic basis of the therapy.[14]

7.3 Limitations and Safety Considerations

While the results are promising, several limitations must be addressed:

- **Signaling Variance:** The study noted high variance in the phosphorylation states of TrkB (p-TrkB) and Src (p-Src) in post-mortem tissue, leading to non-significant results for these markers.[1] This suggests that while structural preservation is robust, signaling snapshots are difficult to capture.
- **Oncogenic Potential:** Cav-1 is implicated in cancer progression (both as a suppressor and a promoter depending on context).[21] While the use of the Synapsin promoter restricts expression to post-mitotic neurons (minimizing cancer risk), long-term safety studies are essential to ensure no off-target effects in glial populations or systemic tissues.
- **Proxy Measurements:** The study did not explicitly measure lysosomal pH or V-ATPase assembly directly (e.g., via ratiometric imaging or native gels). The conclusion of lysosomal rescue is inferred from the restoration of LRP1, RELCH, and synaptic structure. Future studies must explicitly validate the re-acidification of lysosomes in SynCav1-treated neurons.

---

8. Conclusion

The research paper by Head et al. represents a landmark contribution to the field of Alzheimer's research. By demonstrating that gene therapy can preserve cognitive function and synaptic structure without clearing amyloid plaques, it breaks the stranglehold of the amyloid hypothesis and validates alternative approaches focused on cellular resilience.

When evaluated against the **Convergent Autophagic Collapse (CAC)** framework, the study

provides compelling, multi-dimensional evidence of mechanism. The restoration of **Cav-1** and the subsequent upregulation of **RELCH** offers a highly plausible molecular pathway for resolving the endolysosomal cholesterol jams that paralyze the AD neuron. SynCav1 appears to act as a molecular scaffold that re-engineers the failing digestive and signaling architecture of the cell, effectively preventing the autophagic collapse.

Verdict: The research is of exceptional quality and theoretical significance. It strongly supports the CAC framework by providing a viable genetic tool to reverse membrane-lipid-driven autophagic failure. It is recommended for the highest consideration by the Oskar Fischer Prize committee.

References

- [1]: Primary Paper and Bibliography (Head et al., 2020).
- [1]: Figure Data and Biochemical Analysis.
- [1]: Methodology, AAV Details, and Statistics.
- [1]: Proteomics Data (Shisa9, RELCH).
- [1]: Amyloid Plaque Data.
- [23]: RELCH/KIAA1468 function in cholesterol transport.
- [24]: Shisa9 function in synaptic plasticity and AMPAR regulation.
- [2]: Cholesterol-dependent inhibition of V-ATPase and lysosomal acidification.
- [13]: Interaction between Cav-1 and V-ATPase.
- [31]: Clinical translation status (Eikonoklastes Therapeutics).
- [35]: Independent validation of targets in human AD datasets.

Works cited

1. OFP_2020_bibliography_13.pdf
2. Lysosomes, cholesterol and atherosclerosis - PMC - PubMed Central - NIH, accessed January 27, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC3105626/
3. Effect of lysosomal cholesterol accumulation on lysosomal and vacuolar-ATPase activity, accessed January 27, 2026, https://ir.vanderbilt.edu/items/51c2c8ef-8495-42f7-ae34-b93da540cf28/full
4. Regulation of Phagolysosomal Digestion by Caveolin-1 of the Retinal Pigment Epithelium Is Essential for Vision - PMC - NIH, accessed January 27, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC4813570/
5. Intracellular cholesterol transport inhibition Impairs autophagy flux by decreasing autophagosome–lysosome fusion - PMC - NIH, accessed January 27, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC9701069/
6. Enhancing the retrograde axonal transport by curcumin promotes autophagic flux in N2a/APP695swe cells - Aging-US, accessed January 27, 2026, https://www.aging-us.com/article/102235/text

7. Cholesterol trafficking, lysosomal function, and atherosclerosis, accessed January 27, 2026, https://journals.physiology.org/doi/full/10.1152/ajpcell.00415.2023
8. Caveolar and non-Caveolar Caveolin-1 in ocular homeostasis and disease - PMC - PubMed Central, accessed January 27, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC9669151/
9. Caveolin regulation of endothelial function - American Physiological Society Journal, accessed January 27, 2026, https://journals.physiology.org/doi/full/10.1152/ajplung.00242.2003
10. Loss of Caveolin-1 Accelerates Neurodegeneration and Aging | PLOS One, accessed January 27, 2026, https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0015697
11. Regulation of caveolin-1 membrane trafficking by the Na/K-ATPase - PMC - PubMed Central, accessed January 27, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC2542476/
12. Cav-1 (Caveolin-1) Deficiency Increases Autophagy in the Endothelium and Attenuates Vascular Inflammation and Atherosclerosis - American Heart Association Journals, accessed January 27, 2026, https://www.ahajournals.org/doi/10.1161/ATVBAHA.120.314291
13. Critical role of CAV1/caveolin-1 in cell stress responses in human breast cancer cells via modulation of lysosomal function and autophagy, accessed January 27, 2026, https://www.tandfonline.com/doi/full/10.1080/15548627.2015.1034411
14. Critical role of CAV1/caveolin-1 in cell stress responses in human breast cancer cells via modulation of lysosomal function and autophagy - NIH, accessed January 27, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC4509445/
15. Protecting cells by protecting their vulnerable lysosomes: Identification of a new mechanism for preserving lysosomal functional integrity upon oxidative stress - PMC - PubMed Central, accessed January 27, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC5325589/
16. Regulation of the V-ATPase along the Endocytic Pathway Occurs through Reversible Subunit Association and Membrane Localization | PLOS One, accessed January 27, 2026, https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0002758
17. CAV1 deficiency promotes V-ATPase assembly. (A) Lipid raft marker CTxB... | Download Scientific Diagram - ResearchGate, accessed January 27, 2026, https://www.researchgate.net/figure/CAV1-deficiency-promotes-V-ATPase-assembly-A-Lipid-raft-marker-CTxB-red-and-lysosome_fig2_276071721
18. (PDF) Synapsin-caveolin-1 Mitigates Cognitive Deficits and Neurodegeneration in PSAPP Mice - ResearchGate, accessed January 27, 2026, https://www.researchgate.net/publication/345454546_Synapsin-caveolin-1_Mitigates_Cognitive_Deficits_and_Neurodegeneration_in_PSAPP_Mice
19. Lipid Rafts: Linking Alzheimer's Amyloid-β Production, Aggregation, and Toxicity at Neuronal Membranes - PubMed Central, accessed January 27, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC3014710/
20. Implications of AAV Serotypes in Neurological Disorders: Current Clinical

Applications and Challenges - MDPI, accessed January 27, 2026, https://www.mdpi.com/2514-183X/9/3/32
21. CAVEOLIN-1 expression in brain metastasis from lung cancer predicts worse outcome and radioresistance, irrespective of tumor histotype | Oncotarget, accessed January 27, 2026, https://www.oncotarget.com/article/4988/text/
22. Synapsin-Promoted Caveolin-1 Overexpression Maintains Mitochondrial Morphology and Function in PSAPP Alzheimer's Disease Mice - PubMed Central, accessed January 27, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC8467690/
23. The Rab11-binding protein RELCH/KIAA1468 controls intracellular cholesterol distribution, accessed January 27, 2026, https://rupress.org/jcb/article-abstract/217/5/1777/38916
24. The Rab11-binding protein RELCH/KIAA1468 controls intracellular cholesterol distribution - PMC - NIH, accessed January 27, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC5940305/
25. The Rab11-binding protein RELCH/KIAA1468 controls intracellular cholesterol distribution, accessed January 27, 2026, https://pubmed.ncbi.nlm.nih.gov/29514919/
26. Brain cholesterol metabolites cause significant neurodegeneration in human iPSC-derived neurons | bioRxiv, accessed January 27, 2026, https://www.biorxiv.org/content/10.1101/2025.06.10.656594v1.full-text
27. Protein kinase C regulates AMPA receptor auxiliary protein Shisa9/CKAMP44 through interactions with neuronal scaffold PICK1 - PubMed Central, accessed January 27, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC5586339/
28. Shisa9 - Protein shisa-9 - Mus musculus (Mouse) | UniProtKB | UniProt, accessed January 27, 2026, https://www.uniprot.org/uniprotkb/Q9CZN4/entry
29. Shisa9 forms a complex with PSD95 in the hippocampus and cortex.... - ResearchGate, accessed January 27, 2026, https://www.researchgate.net/figure/Shisa9-forms-a-complex-with-PSD95-in-the-hippocampus-and-cortex-Anti-Shisa9-antibody-was_fig3_260109092
30. Caveolin-1 knockout improves CFA-induced inflammatory pain in adult mice through modulating the cGAS STING pathway and autophagy - PMC - PubMed Central, accessed January 27, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC12510588/
31. Alzheimer's Gene Therapy Shows Promise in Preserving Cognitive Function, accessed January 27, 2026, https://today.ucsd.edu/story/alzheimers-gene-therapy-shows-promise-in-preserving-cognitive-function
32. Eikonoklastes Therapeutics Receives FDA Orphan Drug Designation for 1st-in-class Treatment of Amyotrophic Lateral Sclerosis (ALS) - BioSpace, accessed January 27, 2026, https://www.biospace.com/eikonoklastes-therapeutics-receives-fda-orphan-drug-designation-for-1st-in-class-treatment-of-amyotrophic-lateral-sclerosis-als
33. Eikonoklastes Therapeutics, Inc. - Drug pipelines, Patents, Clinical trials - Patsnap Synapse, accessed January 27, 2026, https://synapse.patsnap.com/organization/59a52305943c45ed377aad9e669942ac

34. Eikonoklastes Therapeutics, accessed January 27, 2026, https://eikonoklastes.com/
35. Characterization of gene expression patterns in mild cognitive impairment using a transcriptomics approach and neuroimaging endophenotypes - PMC - PubMed Central, accessed January 27, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC10078657/
36. Sex- and region-specific cortical and hippocampal whole genome transcriptome profiles from control and APP/PS1 Alzheimer's disease mice | PLOS One - Research journals, accessed January 27, 2026, https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0296959
37. (PDF) Single-Cell Transcriptomic Profiling Reveals Regional Differences in the Prefrontal and Entorhinal Cortex of Alzheimer's Disease Brain - ResearchGate, accessed January 27, 2026, https://www.researchgate.net/publication/391892143_Single-Cell_Transcriptomic_Profiling_Reveals_Regional_Differences_in_the_Prefrontal_and_Entorhinal_Cortex_of_Alzheimer's_Disease_Brain
38. The crosstalk of caveolin-1 and autophagy in different diseases - Frontiers, accessed January 27, 2026, https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1648757/full
39. Caveolin-1, a Key Mediator Across Multiple Pathways in Glioblastoma and an Independent Negative Biomarker of Patient Survival, accessed January 27, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC8417742/